At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
TAK-954drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954
In Brief
A Phase 1 clinical trial evaluating TAK-954 for Hepatic Impairment and Healthy Volunteers. Completed, enrolled 25 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of varying degrees of hepatic function on the single dose PK of IV TAK-954.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy Volunteers
CountriesCzechia, Slovakia
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartNov 2017
Primary CompletionSep 2018
Study CompletionSep 2018
TodayJul 2026
First PostedSep 11, 2017
Enrollment StartNov 9, 2017
Primary CompletionSep 1, 2018
Study CompletionSep 10, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.8 years ago
Interventions
TAK-954drug
TAK-954 intravenous infusion.